Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group


Division of Virology, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands; Department of Microbiology and Immunology, Loyola University Medical Center, Maywood, Illinois, USA; Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA; World Health Organization, WHO Regional Office for Europe, Copenhagen, Denmark; Institute of Virology, University of Bonn Medical Center, Bonn, Germany; Department of Molecular and Cell Biology, National Center of Biototechnology (CNB-CSIC), Campus de la Universidad Autonoma de Madrid, Madrid, Spain; Viroscience Lab, Erasmus MC, Rotterdam, The Netherlands; Public Health England (formerly Health Protection Agency), London, United Kingdom; Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands; Public Health Directorate, Ministry of Health, Riyadh, Kingdom of Saudi Arabia; Department of Microbiology, University of Iowa, Iowa City, Iowa, USA; Centre of Influenza Research & School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, People’s Republic of China; Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, People’s Republic of China; Medical Microbiology and Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Institute of Medical Virology, Justus Liebig University Giessen, Giessen, Germany

IDENTIFICATION OF A NOVEL CORONAVIRUS AS A CAUSE OF SEVERE RESPIRATORY DISEASE

During the summer of 2012, in Jeddah, Saudi Arabia, a hitherto unknown coronavirus (CoV) was isolated from the sputum of a patient with acute pneumonia and renal failure (1, 2). The isolate was provisionally called human coronavirus Erasmus Medical Center (EMC) (3). Shortly thereafter, in September 2012, the same type of virus, named human coronavirus England 1, was recovered from a patient with severe respiratory illness who had been transferred from the Gulf region of the Middle East to London, United Kingdom (4) (GenBank accession no. KC164505.2). The onset of the new disease was traced back to an even earlier time point. Already in April 2012, a cluster of pneumonia cases in health care workers had occurred in an intensive care unit of a hospital in Zarqa, Jordan (5). Two persons died, both of whom were confirmed to have been infected with the novel coronavirus through a retrospective analysis of stored samples (6). These findings met with considerable concern. Although the number of laboratory-confirmed cases is limited (34 as of 12 May 2013), the morbidity and mortality of the infection is alarming, as is its uncanny resemblance—at least in its clinical features—to severe acute respiratory syndrome (SARS). While in a small minority of the known cases the patients developed mild disease, most patients presented with a severe acute respiratory condition requiring hospitalization; the mortality rate is approximately 60% (7).

The infection appears to be geographically linked—at least for now—to the Middle East, with cases originating from Jordan (n = 2), Saudi Arabia (n = 25), Qatar (n = 2), and the United Arab Emirates (n = 2). Of the three patients known to have contracted the virus outside the Middle East, two became infected in the United Kingdom through contact exposure to an index patient, shortly after the latter returned from a visit to Pakistan and Saudi Arabia (8). Very recently in France, a tourist returning from the United Arab Emirates fell ill and transmitted the infection to at least one other person, with whom he had shared a hospital room (7). Full-length genome sequences determined for three independent virus isolates from Saudi Arabia (3) (GenBank accession no. JX869059.2), Jordan (GenBank accession no. KC776174.1), and the United Kingdom (9) (GenBank accession no. KC164505.2) revealed more than 99% sequence identity (~100 nucleotide variations in a 30.1-kb genome), indicating that these viruses diverged from a common ancestor very recently.

PHYLGENY AND EPIDEMIOLOGY

Within the subfamily Coronavirinae (10), the novel virus is a representative of a new, yet-to-be-established species in lineage C of the genus Betacoronavirus, which currently includes the species Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5 (Fig. 1) (3). The novel coronavirus seems most closely related to as-yet-unclassified viruses from insectivorous European and African bats in the Vespertilionidae and Nycteridae families, respectively (3, 9, 11–13). Of note, for the latter viruses, only partial genome sequences are available. The scarce epidemiological data available suggest that the infection is primarily zoonotic in nature, with limited human-to-human transmission. From what we already know of coronavirus biology (14) and from the accumulating evidence for this particular virus (3, 9, 13), bats appear to be the natural host, and it would be tempting to assume that these animals are also the immediate source. However, this idea is difficult to reconcile with the fact that most patients were unlikely to have been exposed directly to bats, or with the close genetic relationship between the human isolates, indicative of a recent bottleneck. A more likely scenario is that a single variant from a spectrum of related betacoronaviruses in bats successfully crossed over to and rapidly established itself in (an) intermediate animal host species (at least in the Middle East), with subsequent incidental spillover into the human population. Such spillover events would be facilitated through frequent intermediate host-human interactions and perhaps through viral adaptations acquired during the initial species jump. Although at present there is no evidence for sustained community transmission, the obvious concern is that...
the virus may take the next step and adapt to efficient human-to-human transmission.

**CONSENSUS NAME: MERS-CoV**

Since the initial discovery, isolates of the virus have been described in the scientific literature, databases, and popular press under various names (e.g., human betacoronavirus 2c EMC, human betacoronavirus 2c England-Qatar, human betacoronavirus 2C Jordan-N3, betacoronavirus England 1) with novel coronavirus (NCoV) as the one used most often. As this lack of uniformity in virus nomenclature complicates communication both in the research field and with health care authorities, governments, and the general public, the Coronavirus Study Group (CSG) of the International Committee on Taxonomy of Viruses (http://ictvonline.org/index.asp?bhcp=1) took the lead to address this issue. After careful consideration and broad consultation, the CSG has decided to call the new coronavirus Middle East respiratory syndrome coronavirus (MERS-CoV). This name is endorsed by the discoverers of the virus and other researchers that pioneered MERS-CoV studies, by the World Health Organization, and by the Saudi Ministry of Health. We strongly recommend the use of this name in scientific and other communications. New MERS-CoV isolates or variants detected by reverse transcription (RT)-PCR may be provided with an affix, analogous to convention in influenza virus nomenclature (the host/country of origin plus the strain identification number/year; e.g., MERS-CoV Hu/Jordan-N3/2012). As our knowledge of the epidemiology and host preference of this virus is still incomplete, it seems prudent to refrain from labeling MERS-CoV a human coronavirus, at least for the time being.

**ACKNOWLEDGMENTS**


**REFERENCES**

3. van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, Osterhaus AD, Haagmans BL, Gorbalenya AE, Snijder EJ,


